- Home
- GYRE vs IRON Comparison
GYRE vs IRON Comparison
Compare GYRE & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- IRON
- Stock Information
- Founded
- GYRE 2002
- IRON 2017
- Country
- GYRE United States
- IRON United States
- Employees
- GYRE N/A
- IRON N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- GYRE Health Care
- IRON Health Care
- Exchange
- GYRE Nasdaq
- IRON Nasdaq
- Market Cap
- GYRE 1.3B
- IRON 1.4B
- IPO Year
- GYRE N/A
- IRON N/A
- Fundamental
- Price
- GYRE $11.42
- IRON $64.00
- Analyst Decision
- GYRE
- IRON Strong Buy
- Analyst Count
- GYRE 0
- IRON 10
- Target Price
- GYRE N/A
- IRON $73.70
- AVG Volume (30 Days)
- GYRE 126.3K
- IRON 253.9K
- Earning Date
- GYRE 11-13-2024
- IRON 11-12-2024
- Dividend Yield
- GYRE N/A
- IRON N/A
- EPS Growth
- GYRE N/A
- IRON N/A
- EPS
- GYRE N/A
- IRON N/A
- Revenue
- GYRE $105,033,000.00
- IRON N/A
- Revenue This Year
- GYRE $25.32
- IRON N/A
- Revenue Next Year
- GYRE $12.95
- IRON N/A
- P/E Ratio
- GYRE N/A
- IRON N/A
- Revenue Growth
- GYRE N/A
- IRON N/A
- 52 Week Low
- GYRE $8.26
- IRON $25.60
- 52 Week High
- GYRE $30.40
- IRON $77.60
- Technical
- Relative Strength Index (RSI)
- GYRE 54.43
- IRON 53.08
- Support Level
- GYRE $9.61
- IRON $62.31
- Resistance Level
- GYRE $12.58
- IRON $67.87
- Average True Range (ATR)
- GYRE 1.12
- IRON 3.04
- MACD
- GYRE 0.16
- IRON -0.46
- Stochastic Oscillator
- GYRE 79.51
- IRON 38.78
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.